News Related to CTG32

Related coverage linked through entity extraction aliases.

Three Drugmakers Advance Obesity Pipelines with New Mechanisms and Clinical Plans

Mar 01, 2026

Amgen, Celltrion, and Palatin Technologies are advancing obesity drug candidates through clinical development, with trials planned for 2026-2028 targeting liver fat reduction, multiple biological pathways, and rare genetic obesity conditions.

Celltrion Enters Obesity Drug Market with Dual Pipeline

Feb 24, 2026

Celltrion announced plans to develop both injectable and oral obesity treatments based on GLP-1, with clinical trial filings planned for 2027 and 2028 respectively.